BGI Leads $30 Million Funding in Beijing Gene+ Technology

BGI, China's large genomics sequencing company (previously known as Beijing Genomics Institute), led a $30 million Series A round in Beijing Gene+ Technology, an oncology gene testing and precision medicine start-up. The funding is said to be the largest in a China precision medicine and liquid biopsy testing company to date. It may also be a first for BGI, which usually forms partnerships rather than making direct investments. BGI has its own diagnostics subsidiary. Green Pine Capital Partners of Shenzhen and Shanghai Huoshanshi Capital also participated. More details.... Share this with colleagues: // //